Ohtake, S., Kawahara, T., Kasahara, R., Ito, H., Osaka, K., Hattori, Y., . . . Uemura, H. (2016). Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. Biomed Res Int.
Citação norma ChicagoOhtake, Shinji, et al. "Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy." Biomed Res Int 2016.
Citação norma MLAOhtake, Shinji, et al. "Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy." Biomed Res Int 2016.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.